The Department of Veterans Affairs (VA) is issuing a Presolicitation Notice for Request for Proposal (RFP) 36E79725R0005 to procure Abiraterone Acetate Tablets. This procurement is unrestricted and encompasses supply needs across multiple federal entities, including the Department of Defense and Bureau of Prisons. One contract will be awarded to ensure a consistent supply of the medication over a five-year period, including a base year and four optional years. Offerors must provide specific labeling and packaging requirements, including a safety-cap and precise dimensions for the bottle and label. The solicitation is scheduled for electronic issuance around November 22, 2024, with a closing date set for December 6, 2024. Interested parties should monitor sam.gov for updates or amendments, as no paper copies will be available. The estimated annual need is 71,997 bottles of 250mg Abiraterone Acetate Tablets. Richard Mahario serves as the primary contact for inquiries regarding this RFP.
This document outlines a Request for Proposal (RFP) by the Department of Veterans Affairs (VA) for the supply of Abiraterone Acetate Tablets through the VA's Pharmaceutical Prime Vendor Program. The RFP emphasizes compliance with regulations and standards, including the Drug Supply Chain Security Act (DSCSA) and Good Manufacturing Practices (cGMP). Offerors must provide a unique 11-digit National Drug Code (NDC) for each drug, submit pricing for both the base year and four optional years, and include a Cost Recovery Fee. The contract duration includes an implementation period followed by a one-year ordering period, with options for four additional years. It mandates that only FDA-inspected manufacturing facilities with acceptable cGMP status will be considered. The document reinforces that all sales and executed agreements are subject to oversight and compliance checks, maintaining high standards for drug quality and supply chain security. The objectives center on ensuring consistent drug availability and competitive pricing for federal healthcare users, highlighting the VA's commitment to quality service for veterans and related entities.
The document is an amendment to the Request for Proposals (RFP) for Abiraterone Tablets issued by the Department of Veterans Affairs (VA). The key purpose of this amendment is to extend the deadline for receipt of offers from the original date to January 8, 2025, at 2:30 PM CST. The amendment includes instructions for offerors to acknowledge receipt of the amendment and clarify that this change is made to ensure that all proposals submitted for the RFP are considered. Apart from the date change, all other terms and conditions of the original solicitation remain unchanged and fully effective. The document highlights the importance of complying with the new deadline to avoid rejection of offers. The contracting officer, Nicholas I. McGregor, has signed off on this amendment, reinforcing its official status as part of the bidding process for the requested product.